CARCINOMA, HEPATOCELLULAR
Clinical trials for CARCINOMA, HEPATOCELLULAR explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, HEPATOCELLULAR trials appear
Sign up with your email to follow new studies for CARCINOMA, HEPATOCELLULAR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough liver cancer
Disease control OngoingThis study tests a combination of two drugs (atezolizumab and bevacizumab) in people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink or control the cancer. Participants receive the drugs by IV and are monitored for side…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: NA • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Could a drug combo stop liver cancer from coming back after transplant?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether a drug called everolimus can help prevent liver cancer from returning in people who have had a liver transplant for a type of liver cancer that is harder to treat. About 336 adults who are at high risk for their cancer coming back will be randomly assi…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE4 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated May 17, 2026 00:50 UTC
-
New hope for kids with liver cancer: smarter, safer treatments on the horizon
Disease control OngoingThis study is for children with two types of liver tumors: hepatoblastoma and hepatocellular carcinoma. It uses a risk-based approach, meaning the treatment is tailored to each child's specific situation to improve survival and reduce side effects. About 450 children are taking p…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated May 17, 2026 00:50 UTC
-
New drug combo aims to stop liver cancer recurrence after surgery
Disease control OngoingThis study tests whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who have had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence will receive either the drug combination …
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New combo therapy aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug, E7386, combined with other anticancer drugs for people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose. About 301 participants will be involved, and the study foc…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New blood test could spot liver cancer sooner in High-Risk patients
Diagnosis ENROLLING_BY_INVITATIONThis study is testing whether a new blood test, called the GAAD score, can improve the detection of liver cancer in people who are at high risk, such as those with cirrhosis or chronic hepatitis. Around 2,100 participants will get an ultrasound and the GAAD blood test every six m…
Matched conditions: CARCINOMA, HEPATOCELLULAR
Phase: NA • Sponsor: Siriraj Hospital • Aim: Diagnosis
Last updated May 17, 2026 00:52 UTC